相关实验视频

Updated: Feb 18, 2026

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

在IDH突变的WHO4级星系细胞瘤中治疗ivosidenib:说明案例

Brittany Owusu- Adjei^1,2, Janelle P Renterghem¹, Cristina Hayes Meizoso¹

¹Department of Neurological Surgery, University of Massachusetts Chan Medical School, Worcester.

Journal of neurosurgery. Case lessons

|February 16, 2026

概括

作为IDH-1抑制剂的IVOSIDENIB在患有IDH突变性WHO4级星系细胞瘤的患者中显示出瘤的减少. 这一案例表明,这种向治疗在高度质瘤中具有潜在的疗效,需要进一步调查.

科学领域:

神经瘤学神经瘤学
分子向疗法分子向疗法
大脑瘤的遗传学

背景情况:

异酸脱酶 (IDH) 突变在质瘤中很常见,影响瘤行为和预后.
IDH-突变的WHO 4 级星系细胞瘤的预后很差,尽管在年轻患者中发生.
伊沃西迪尼布是一种IDH-1抑制剂,有效治疗低级质瘤,但其在高级质瘤中的作用尚未被探索.

研究的目的:

报告ivosidenib的非标签使用和影响在患有复发IDH突变WHO4级星细胞瘤的患者中.
探索IDH抑制剂在治疗高度质瘤中的潜力.

主要方法:

一个36岁男性的案例研究,患有IDH突变WHO4级星系细胞瘤.
治疗包括标准疗法 (切除,辐射,泰莫索洛米德),然后在隆慕斯失效后接受ivosidenib.
通过放射监测监测瘤反应.

主要成果:

伊沃西登尼布在洛穆斯治疗失败后,开始治疗复发的IDH突变WHO4级星系细胞瘤.
放射性成像显示,在开始服用ivosidenib两个月后,瘤大小有所减少.
患者保持了神经功能,并没有经历任何不良影响.

结论:

这一案例表明,ivosidenib在治疗高度IDH突变天体细胞瘤方面可能具有有效性.
需要进一步的临床研究来证实IDH抑制剂对高度质瘤生存结果的影响.

关键词:

发生IDH突变的IDH突变.高度质瘤高度质瘤异酸盐脱基酶是什么它们可以被杀.

更多相关视频

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...